Marvelon

Desogestrel/Ethinylestradiol, the active ingredient in Marvelon, is a combined oral contraceptive presented as a 150 µg / 30 µg tablet for oral use. It provides reversible prevention of pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the endometrial lining in women of reproductive age. It is approved throughout the European Union and is widely prescribed for reliable birth control.

GNH USA supplies Marvelon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Marvelon, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy. - Prevention of pregnancy: provides reliable contraceptive protection by suppressing ovulation and modifying cervical mucus. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns and may reduce cycle length variability. - Management of dysmenorrhea: can lessen menstrual pain associated with ovulatory cycles.

Marvelon may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Irregular bleeding: spotting or breakthrough bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hepatic adenoma: benign liver tumor, rarely reported. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Marvelon, clinicians should consider several precautionary measures to ensure safe use. - Contraindication in pregnancy: the product must not be used by pregnant women (Category X). - Smoking status: avoid use in women over 35 who smoke heavily due to increased cardiovascular risk. - History of thromboembolism: assess prior clotting events before initiating therapy. - Liver disease: evaluate hepatic function as metabolism may be impaired. - Migraine with aura: use with caution as risk of stroke may be elevated. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Marvelon can interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce contraceptive efficacy. - Antifungal azoles (e.g., ketoconazole): may increase hormone levels, raising side‑effect risk. - Certain antiretrovirals (e.g., efavirenz): decrease plasma concentrations, compromising contraception.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., sertraline): may modestly affect hormone metabolism. - Anticonvulsants (e.g., valproate): potential for reduced efficacy, monitor menstrual patterns. - Herbal supplements (e.g., St. John’s wort): may lower contraceptive effectiveness, advise caution.